ProQuest Associates IV

Latest statistics and disclosures from ProQuest Associates IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are URGN, MRSN, Immune Design, Agile Therapeutics, and represent 100.00% of ProQuest Associates IV's stock portfolio.
  • Reduced shares in these 1 stock: EGRX.
  • Sold out of its position in EGRX.
  • ProQuest Associates IV was a net seller of stock by $-513k.
  • ProQuest Associates IV has $53M in assets under management (AUM), dropping by -18.46%.
  • Central Index Key (CIK): 0001431819

Tip: Access up to 7 years of quarterly data

Positions held by ProQuest Associates IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for ProQuest Associates IV

ProQuest Associates IV holds 4 positions in its portfolio as reported in the September 2018 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Urogen Pharma (URGN) 70.4 $37M 789k 47.23
 View chart
Mersana Therapeutics (MRSN) 18.0 $9.6M 956k 10.00
 View chart
Immune Design 8.1 $4.3M 1.2M 3.45
 View chart
Agile Therapeutics 3.5 $1.9M 5.1M 0.37
 View chart

Past Filings by ProQuest Associates IV

SEC 13F filings are viewable for ProQuest Associates IV going back to 2014